Prednisolone Sodium PhosphateOphthalmic Solution USP, 1% (Sterile) | Prednisolone Sodium Phosphate [Butler Animal Health Supply] | BioPortfolio

12:20 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Rx only

Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, is a sterile solution for ophthalmic administration having the following composition:

Each mL Contains:

ACTIVE: Prednisolone Sodium Phosphate 10 mg (1%) [equivalent to 9.1 mg/mL prednisolone phosphate] in a buffered isotonic solution containing INACTIVES: Hypromellose, Monobasic and Dibasic Sodium Phosphate, Sodium Chloride, Edetate Disodium and Purified Water. Sodium Hydroxide and/or Hydrochloric Acid may be added to adjust the pH (6.2 - 8.2).PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.

The chemical name for prednisolone sodium phosphate is Pregna-1, 4-diene - 3, 20-dione, 11, 17-dihydroxy-21-(phosphonooxy)-, disodium salt, (11 β) -, which has the following structural formula:

Molecular formula: CHNaOP

Molecular Weight: 484.39

Prednisolone sodium phosphate causes inhibition of inflammatory response to inciting agents of mechanical, chemical, or immunological nature. No generally accepted explanation of this steroid property has been advanced.

Prednisolone Sodium Phosphate Ophthalmic Solution 1% or 1/8% is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, is recommended for moderate to severe inflammations, particularly when unusually rapid control is desired. In stubborn cases of anterior segment eye disease, systemic adrenocortical hormone therapy may be required. When deeper ocular structures are involved, systemic therapy is necessary.

The use of this preparation is contraindicated in the presence of:

1] Acute superficial herpes simplex keratitis.

2] Fungal diseases of ocular structures.

3] Acute infectious stages of vaccinia, varicella and most other viral diseases of the cornea and conjunctiva.

4] Tuberculosis of the eye.

5] Hypersensitivity to a component of this medication.

The use of this preparation is always contraindicated after uncomplicated removal of a superficial corneal foreign body.


Employment of steroid medication in the treatment of herpes simplex keratitis involving the stroma requires great caution; frequent slit-lamp microscopy is mandatory.

Prolonged use may result in elevated intraocular pressure and/or glaucoma, damage to the optic nerve, defects in visual acuity and fields of vision, posterior subcapsular cataract formation, or may aid in the establishment of secondary ocular infections from pathogens liberated from ocular tissues. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical steroids. Acute purulent untreated infection of the eye may be masked or activity enhanced by presence of steroid medication. Viral, bacterial, and fungal infections of the cornea may be exacerbated by the application of steroids.

This drug is not effective in mustard gas keratitis and Sjögren’s keratoconjuncitivitis.

If irritation persists or develops, the patient should be advised to discontinue use and consult prescribing physician.

As fungal infections of the cornea are particularly prone to develop coincidentally with long-term steroid applications, fungus invasion must be suspected in any persistent corneal ulceration where a steroid has been used or is in use.

Intraocular pressure should be checked frequently.

Do not touch dropper tip to any surface as this may contaminate the solution.

Pregnancy Category C: Animal reproductive studies have not been conducted with prednisolone sodium phosphate. It is also not known whether prednisolone sodium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Prednisolone sodium phosphate should be given to a pregnant woman only if clearly needed.

The effect of prednisolone sodium phosphate on the later growth, development and functional maturation of the child is unknown.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when prednisolone sodium phosphate is administered to a nursing woman.

Safety and effectiveness in pediatric patients have not been established.

Glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infections from pathogens including herpes simplex and fungi, and perforation of the globe.

Rarely, filtering blebs have been reported when topical steroids have been used following cataract surgery.

Rarely, stinging, or burning may occur.

Depending on the severity of inflammation, instill one or two drops of solution into the conjunctival sac up to every hour during the day and every two hours during the night as necessary as initial therapy.

When a favorable response is observed, reduce dosage to one drop every four hours.

Later, further reduction in dosage to one drop three to four times daily may suffice to control symptoms.

The duration of treatment will vary with the type of lesion and may extend from a few days to several weeks, according to therapeutic response. Relapses, more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% is supplied in a plastic squeeze bottle with a controlled drop tip in the following sizes:

5 mL bottle - Prod. No. 04307

10 mL bottle - Prod. No. 04309

15 mL bottle - Prod. No. 04311

Store between 15° - 30° C (59° - 86° F).

Protect from light. Keep tightly closed.



Bausch & Lomb Incorporated Tampa, FL 33637©Bausch & Lomb Incorporated

9101401 (Folded) 9101501 (Flat)

NDC 11695-1431-5

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1%

Rx only



Reorder No. 029897

Distributed Exclusively by:

Butler AHS Dublin, OH 43017



Butler Animal Health Supply

Active Ingredients


Drugs and Medications [156 Associated Drugs and Medications listed on BioPortfolio]

Prednisolone sodium phosphate [mwi/vetone]

Prednisolone Sodium PhosphateOphthalmic Solution USP, 1% (Sterile)

Prednisolone sodium phosphate [bausch & lomb incorporated]

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile)

Sulfacetamide sodium and prednisolone sodium phosphate [rpk pharmaceuticals, inc.]

Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution 10%/0.23% (prednisolone phosphate) (Sterile)

Sulfacetamide sodium and prednisolone sodium phosphate [bausch & lomb incoporated]

Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution 10%/0.23% (prednisolone phosphate) (Sterile)

P32 sodium phosphate [anazaohealth corporation]

P32 Chromic Phosphate Suspension

Clinical Trials [2619 Associated Clinical Trials listed on BioPortfolio]

The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation

This study will investigate if liposomal prednisolone is effective in promoting arteriovenous fistula (AVF) maturation when administered to human subjects after surgical creation of a radi...

Parasitic Ulcer Treatment Trial Pilot

This is a study of optimal treatments for acanthamoeba keratitis. In the first part of the study, participants will be randomized to chlorhexidine monotherapy or chlorhexidine plus povidon...

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of 2 different TR-701 oral formulations (free acid phosphate powder in capsule and di-sodium ph...

Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children

A trial to investigate if a single dose of the oral corticosteroid, Dexamethasone is as effective in treating exacerbations of asthma in children as 3 days of treatment with another oral c...

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery Syste...

PubMed Articles [3197 Associated PubMed Articles listed on BioPortfolio]

λ‑Carrageenan‑calcium phosphate and sodium alginate‑calcium phosphate modified with dimethyl diallyl ammonium chloride and diallylamin co-polymer as efficient adsorbents of anionic dyes.

Alginate and carrageenan bio-polymers have been proved to be, only, good sorbents of cationic dyes. In this study, we reported the synthesis of [λ‑carrageenan‑calcium phosphate] and [sodium algin...

The effects of prednisolone treatment on serological responses and lipid profiles in Ethiopian leprosy patients with Erythema Nodosum Leprosum reactions.

Erythema nodosum leprosum (ENL) is a systemic inflammatory complication occurring mainly in patients with lepromatous leprosy (LL) and borderline lepromatous leprosy (BL). Prednisolone is widely used ...

Contribution of NHE3 and dietary phosphate to lithium pharmacokinetics.

Lithium is one of the mainstays for the treatment of bipolar disorder despite its side effects on the endocrine, neurological, and renal systems. Experimentally, lithium has been used as a measure to ...

Single dose prednisolone alters endocrine and haematologic responses and exercise performance in men.

The aim of this study was to investigate the effect of a single dose of prednisolone on (A) high-intensity interval cycling performance and (B) post-exercise metabolic, hormonal and haematological res...

FTY720P inhibits the Na/K ATPase in Caco-2 cells via S1PR2: PGE2 and NO are along the signaling pathway.

Sphingosine-1-phosphate (S1P) has been implicated lately in inflammatory bowel disease which has diarrhea as one of its symptoms. Diarrhea is due to altered water movements as a result of altered elec...

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record